J&J Ups Negotiation Dance With Guidant To Get Reduced Price After Recalls
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson will need to weigh the risks of trying to renegotiate its $24 bil. acquisition of Guidant with its interest in entering the rapidly-expanding ICD market
You may also be interested in...
Cardiac Rhythm Management Firms Targeted By DoJ Fraud Investigation
Subpoenas served to Guidant, Medtronic and St. Jude Medical by the U.S. Department of Justice appear to be investigating potential improper inducements to increase sales of pacemakers and ICDs
Cardiac Rhythm Management Firms Targeted By DoJ Fraud Investigation
Subpoenas served to Guidant, Medtronic and St. Jude Medical by the U.S. Department of Justice appear to be investigating potential improper inducements to increase sales of pacemakers and ICDs
Guidant Clarifies J&J Merger Terms, Incentives For Execs, Antitrust Defense
Antitrust regulators weighing the potential impact of a J&J/Guidant merger on the DES market are likely to be mollified by the number of firms with drug-eluting stents in development, Guidant CEO Ron Dollens says